<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3069">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04576312</url>
  </required_header>
  <id_info>
    <org_study_id>UNI911-101</org_study_id>
    <nct_id>NCT04576312</nct_id>
  </id_info>
  <brief_title>Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults With COVID-19</brief_title>
  <official_title>Phase 1 Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in Preparation for Evaluation in Adults With COVID-19</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UNION therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UNION therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1 Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to&#xD;
      Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in&#xD;
      Preparation for Evaluation in Adults with COVID-19&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1 Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to&#xD;
      Assess the Safety of Ascending Doses of UNI911 INHALATION in Healthy Volunteers in&#xD;
      Preparation for Evaluation in Adults with COVID-19&#xD;
&#xD;
      64 subjects will be sequentially enrolled to receive dosage of UNI911 INHALATION or placebo.&#xD;
      4 sentinel subjects (one per cohort 1, 2 ,3 and 4 ) will be treated in an open-label manner&#xD;
      to confirm the safety of each dose sequentially. 40 subjects will be randomly assigned (3:1)&#xD;
      to either active or placebo. For the last 2 cohorts, a total of 20 healthy volunteers will be&#xD;
      enrolled to receive multiple doses of UNI911 INHALATION.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 29, 2020</start_date>
  <completion_date type="Anticipated">April 30, 2021</completion_date>
  <primary_completion_date type="Actual">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess safety of UNI911 INHALATION in healthy volunteers: AE frequency</measure>
    <time_frame>Up to Day 6</time_frame>
    <description>AE frequency in each cohort and treatment group</description>
  </primary_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Parameters: Cmax</measure>
    <time_frame>Up to Day 4 of participant treatment</time_frame>
    <description>Maximum concentration of active drug molecules in blood (Cmax)</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Parameters: Tmax</measure>
    <time_frame>Up to Day 4 of participant treatment</time_frame>
    <description>Time to reach maximum level (Tmax)</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Parameters: AUC</measure>
    <time_frame>Up to Day 4 of participant treatment</time_frame>
    <description>Area Under the Curve of drug level in blood versus time (AUC)</description>
  </other_outcome>
  <other_outcome>
    <measure>Pharmacokinetic Parameters: Half life</measure>
    <time_frame>Up to Day 4 of participant treatment</time_frame>
    <description>Half life</description>
  </other_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IP Single and Total Dose* (Inhalation): 4 mL0.1% / 3.4 mg Duration of Treatment: 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IP Single and Total Dose* (Inhalation): 1 mL1% /8.4 mg Duration of Treatment: 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IP Single and Total Dose* (Inhalation): 3 mL1%/25.2 mg Duration of Treatment: 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IP Single and Total Dose* (Inhalation): 6 mL 1% /50.5 mg Duration of Treatment: 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IP Single and Total Dose* (Inhalation): 6 mL1% /50.5mg 30 mL/252mg Duration of Treatment: 2.5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IP Single and Total Dose* (Inhalation): 1 mL1% /8.4 mg Duration of Treatment: 7 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IP Single and Total Dose* (Inhalation): 3 mL1%/25.2 mg Duration of Treatment: 7 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>UNI911 INHALATION</intervention_name>
    <description>UNI911 INHALATION</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_label>Cohort 6</arm_group_label>
    <arm_group_label>Cohort 7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria (main ones):&#xD;
&#xD;
          1. Signed Informed Consent Form (ICF)&#xD;
&#xD;
          2. Male or non-pregnant and non-lactating female who is abstinent or agrees to use&#xD;
             effective contraceptive methods throughout the course of the study. Females must have&#xD;
             a negative urine beta-human chorionic gonadotropin hormone (hCG) pregnancy test prior&#xD;
             to dosing. (Women who are postmenopausal or who had tubal ligation/hysterectomy do not&#xD;
             need to have a pregnancy test done and do not need to agree to use contraception.)&#xD;
&#xD;
          3. ECG without clinically significant abnormalities (including QTcF &lt; 450 ms)&#xD;
&#xD;
          4. Age ≥ 18 and &lt; 65 years at the time of signing ICF&#xD;
&#xD;
          5. Normally active and in good health by medical history and physical examination&#xD;
&#xD;
          6. Minimum 80% of predicted lung function, including FEV1 after beta2-agonist, TLC, DCO,&#xD;
             and CPET with pulse oximetry&#xD;
&#xD;
          7. Chest X-ray without clinically significant abnormalities&#xD;
&#xD;
        Exclusion Criteria (main ones):&#xD;
&#xD;
          1. Enrollment in an UNI911 study in the previous 6 months&#xD;
&#xD;
          2. Clinically significant allergy (as judged by the investigator) or history of&#xD;
             significant adverse reaction to niclosamide or related compounds, to any of the&#xD;
             excipients used.&#xD;
&#xD;
          3. Underlying condition that may interfere with inhalation of the IP&#xD;
&#xD;
          4. Current acute or chronic condition (incl. COPD, asthma, or other severe respiratory&#xD;
             disease, CV disease, diabetes mellitus, obesity, malignant and autoimmune diseases)&#xD;
             unless considered clinically irrelevant and stable by the investigator&#xD;
&#xD;
          5. Renal impairment (eGFR &lt; 60 mL/min/1.73m2) or hepatic impairment (as judged by the&#xD;
             investigator)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulf Sjöbring, MD</last_name>
    <role>Study Chair</role>
    <affiliation>UNION therapeutics A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DanTrials</name>
      <address>
        <city>Copenhagen</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>September 28, 2020</study_first_submitted>
  <study_first_submitted_qc>October 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2020</study_first_posted>
  <last_update_submitted>January 15, 2021</last_update_submitted>
  <last_update_submitted_qc>January 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Aspiration</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

